Lividomycinの抗結核作用に関する基礎的研究

概要

論文の詳細を見る
Lividomycin (LVM) is a new antibiotic agent which was produced from Streptomyces lividus n-sp ATCC 21178 isolated in Nagoya city. LVM was highly active in vitro against Gram-positive and negative organisms, as well as Mycobacterium. This paper presents the results of fundamental studies of antituberculous activities of LVM. 1. The minimal inhibitory concentration of LVM against H37Rv was 0.6 mcg/ml in Dubos albumin medium and 40 mcg/ml in Ogawa medium. This MIC was almost as same as that of Kanamycin. Against eight wild strains isolated from tuberculous patients, MIC of LVM was 1.2 5∼20 mcg/ml in Dubos-albumin medium, and MIC of LVM was higher for KM resista nt strains than for KM sensitive strains. 2. The elevation of the re s istance of H37Rvi n vitro to LVM was examined by the StepbyStep method, and the maximal resistance at the ninth generation was 25 mcg/ml. The elevation of the resistance of H37Rv in vitro to Ethambutol was also examined by the same method, and maximal resistance at the ninth generation of the culture was 50 mcg/ml. By adding 0.2∼0.3 mcg/ml LVM to EB, the resistance of EB remained at 2.5 mcg/ml after ninth generation. 3. There was no cross resistance between LVM and Viomycin. Strains highly resistant to LVM were also resistant to KM. Strains resistant to KM were partially resistant to LVM. 4. The binding capacity with horse serum was measured by the equilibrium dialysis m e thod using the cellophane membrane. The results was 1.9-3.8% in case of 100 mcg/ml LVM and 12.9% in 50 mcg/ml. 5. The b lood level of LVM in tuberculous patients after intramuscular injection were examined by Toriis diffusion method, using Bacillus subtilis (PCI-219 strain). The mean values of the blood level after one hour and six hour were 42 mcg/ml and 8 mcg/ml, respectively. 6. Therapeutic effects of LVM on the experimental tuberculosis of mice were r e congnized, but were slightly inferior to those of KM and VM. It was proved by these fundamental studies that LVM had the antituberculous activities, but the therapeutic effects were slightly inferior to those of KM. But considering the partially cross resistance between LVM and KM, LVM may be clinically applied in some cases after making clinicalir investigations.
日本結核病学会の論文

Lividomycinの抗結核作用に関する基礎的研究

スポンサーリンク

概要

著者

関連論文

スポンサーリンク